The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin
Open accessAbstract
OBJECTIVE—Numerous studies have identified an increased risk of cancer in type 2 diabetes. We explored the association between antidiabetic therapies and cancer-related mortality in patients with type 2 diabetes, postulating that agents that increase insulin levels might promote cancer. RESEARCH DESIGN AND METHODS—This was a population-based cohort study using administrative databases from Saskatchewan Health. Cancer-related mortality was compared among inception cohorts of metformin users and sulfonylurea monotherapy users. Multivariate Cox regression was used to estimate the hazard ratio (HR) of cancer-related mortality, after adjusting for age, sex, insulin use, and chronic disease score. All statistical tests were two-sided. RESULTS—We identified 10,309 new users of metformin or sulfonylureas with an average follow-up of 5.4 ± 1.9 years (means ± SD). The mean age for the cohort was 63.4 ± 13.3 years, and 55% were men. Cancer mortality over follow-up was 4.9% (162 of 3,340) for sulfonylurea monotherapy users, 3.5% (245 of 6,969) for metformin users, and 5.8% (84 of 1,443) for subjects who used insulin. After multivariate adjustment, the sulfonylurea cohort had greater cancer-related mortality compared with the metformin cohort (adjusted HR 1.3 [95% CI 1.1–1.6]; P = 0.012). Insulin use was associated with an adjusted HR of cancer-related mortality of 1.9 (95% CI 1.5–2.4; P < 0.0001). CONCLUSIONS—Patients with type 2 diabetes exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-related mortality compared with patients exposed to metformin. It is uncertain whether this increased risk is related to a deleterious effect of sulfonylurea and insulin or a protective effect of metformin or due to some unmeasured effect related to both choice of therapy and cancer risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with type 2 diabetes who are prescribed metformin had a lower risk of cancer compared to patients who did not take it.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [147]
In the citing paper
“The reduced risk of cancer and cancer mortality observed in these studies has been consistently in the range of 25% to 30% [135-139,145-147].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [147]
In the citing paper
“Patients with type 2 diabetes exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-related mortality compared with patients exposed to metformin.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [147]
In the citing paper
“Results of a growing number of observational human studies suggest that treatment with metformin (relative to other glucose-lowering therapies) is associated with reduced risk of cancer (89–93) or cancer mortality (94).”
From Diabetes and Cancer (2010) · cites this paper as [90]
In the citing paper
“A small number of observational studies found a higher risk of cancer or cancer death among individuals with diabetes treated with sulfonylureas compared with those treated with metformin or other diabetes medications (90–92,110).”
From Diabetes and Cancer (2010) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, D. R., & Hardie, D. G. (2003) · Journal of Biology · doi:10.1186/1475-4924-2-28 · Cited by 1,694
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
A chronic disease score from automated pharmacy data
Korff, M. V., Wagner, E. H., & Saunders, K. W. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90016-g · Cited by 962
Giovannucci, E. L. (1995) · Cancer Causes & Control · doi:10.1007/bf00052777 · Cited by 808
Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults
Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J. M., & Thun, M. J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh161 · Cited by 795
Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis
Everhart, J. (1995) · JAMA · doi:10.1001/jama.273.20.1605 · Cited by 747
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
Self-citationProspective Study of Adult Onset Diabetes Mellitus (Type 2) and Risk of Colorectal Cancer in Women
Hu, F. B., Manson, J. E., Liu, S., Hunter, D. J., Colditz, G. A., Michels, K. B., Speizer, F. E., & Giovannucci, E. L. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.542 · Cited by 420
Cited by
Sorted by citations
Items 401–500 of 933
Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?
Stambolic, V., Woodgett, J. R., Fantus, I. G., Pritchard, K. I., & Goodwin, P. J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0015-4 · Cited by 41
Welch, M. R., & Grommes, C. (2013) · CNS Oncology · doi:10.2217/cns.13.12 · Cited by 41
Metformin and pancreatic cancer: Is there a role?
Souza, A. O., Khawaja, K. I., Masud, F., & Saif, M. W. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2948-8 · Cited by 43
Farooki, A., & Schneider, S. H. (2006) · Diabetes Care · doi:10.2337/dc06-0874 · Cited by 41
Bosetti, C., Franchi, M., Nicotra, F., Asciutto, R., Merlino, L. G., Vecchia, C. L., & Corrao, G. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3801 · Cited by 41
Xiong, Y., Lu, Q., Zhao, J., & Wu, G. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.7.3275 · Cited by 39
Kim, J., Lee, J., Jang, S. Y., Kim, C., Choi, Y.-J., & Kim, A. (2016) · Oncology Reports · doi:10.3892/or.2016.4675 · Cited by 41
Anti-Diabetic Therapies and Cancer: From Bench to Bedside
Kounatidis, D. C., Vallianou, N. G., Karampela, Ι., Rebelos, E., Kouveletsou, M., Dalopoulos, V., Koufopoulos, P., Diakoumopoulou, E., Tentolouris, N., & Dalamaga, Μ. (2024) · Biomolecules · doi:10.3390/biom14111479 · Cited by 47
Tseng, C. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.530683 · Cited by 39
Khawaja, M. R., Nick, A. M., Madhusudanannair, V., Fu, S., Hong, D. S., McQuinn, L., Ng, C. S., Piha-Paul, S. A., Jankú, F., Subbiah, V., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3009-7 · Cited by 40
Liu, X., Liu, Y., Gao, J., Feng, M., Bao, X., Deng, K., Yao, Y., & Wang, R. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.02.188 · Cited by 38
Protein networks linking Warburg and reverse Warburg effects to cancer cell metabolism
Johar, D., Elmehrath, A. O., Khalil, R. M., Elberry, M. H., Zaky, S., Shalabi, S. A., & Bernstein, L. H. (2021) · BioFactors · doi:10.1002/biof.1768 · Cited by 42
Type 2 Diabetes Mellitus and Cancer: Epidemiology, Physiopathology and Prevention
Rey‐Reñones, C., Baena-Díez, J. M., Aguilar‐Palacio, I., Miquel, C., & Grau, M. (2021) · Biomedicines · doi:10.3390/biomedicines9101429 · Cited by 43
Tuccori, M., Wu, J. W., Yin, H., Majdan, A., & Azoulay, L. (2015) · Diabetes Care · doi:10.2337/dc15-1358 · Cited by 38
The metabolic and mitogenic properties of basal insulin analogues
Tennagels, N., & Ulrich, W. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.754474 · Cited by 38
From Genotype to Functional Phenotype: Unraveling the Metabolomic Features of Colorectal Cancer
Bathe, O. F., & Farshidfar, F. (2014) · Genes · doi:10.3390/genes5030536 · Cited by 39
Tseng, C. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2011.10.003 · Cited by 38
Markowska, A., Pawałowska, M., Filas, V., Korski, K., Gryboś, M., Sajdak, S., Olejek, A., Bednarek, W., Śpiewankiewicz, B., Lubin, J., et al. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-76 · Cited by 38
The influence of antidiabetic medications on the development and progression of prostate cancer
Hitron, A., Adams, V. R., Talbert, J., & Steinke, D. T. (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2012.02.005 · Cited by 40
Insulin activates the insulin receptor to downregulate the PTEN tumour suppressor
Liu, J., Grieve, S., Boudreau, J. R., Yeung, B., Lo, S., Chamberlain, G., Yu, F. P. S., Sun, T., Papanicolaou, T., Lam, A., et al. (2013) · Oncogene · doi:10.1038/onc.2013.347 · Cited by 38
Varlotto, J. M., Medford-Davis, L. N., Recht, A., Flíckinger, J. C., Schaefer, É., Shelkey, J., Lazar, M. J., Campbell, D. B., Nikolov, M. C., & Decamp, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.07.019 · Cited by 39
Adrenocortical tumors and insulin resistance: What is the first step?
Altieri, B., Tirabassi, G., Casa, S. D., Ronchi, C. L., Balercia, G., Orio, F., Pontecorvi, A., Colao, A., & Muscogiuri, G. (2015) · International Journal of Cancer · doi:10.1002/ijc.29950 · Cited by 39
Lee, B. B., Kim, Y., Kim, D., Cho, E. Y., Han, J., Kim, H. K., Shim, Y. M., & Kim, D. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14194 · Cited by 38
Metformin: A promising drug for human cancers (Review)
Wu, H., Huang, D., Zhou, H., Sima, X., Wu, Z., Sun, Y., Wang, L., Ruan, Y., Wu, Q., Wu, F., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13325 · Cited by 38
Metformin and cancer: licence to heal?
Papanas, N., Maltezos, E., & Mikhailidis, D. P. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.499122 · Cited by 37
Müssig, K., Staiger, H., Kantartzis, K., Fritsche, A., Kanz, L., & Häring, H. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03132.x · Cited by 37
Yu, O. H. Y., Yin, H., & Azoulay, L. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.02.002 · Cited by 38
Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure
Walker, J. J., Johnson, J. A., & Wild, S. H. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70028-7 · Cited by 37
Self-citationAmbe, C. M., Mahipal, A., Fulp, J., Chen, L., & Malafa, M. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151632 · Cited by 39
Xiao, Z., Gaertner, S., Morresi‐Hauf, A., Genzel, R., Duell, T., Ullrich, A., & Knyazev, P. G. (2017) · Neoplasia · doi:10.1016/j.neo.2017.02.011 · Cited by 37
Associations between Diabetes and Quality of Life among Breast Cancer Survivors
Tang, Z., Wang, J., Zhang, H., Sun, L., Tang, F., Deng, Q., & Yu, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157791 · Cited by 37
Cracking Open Window of Opportunity Trials
Kalinsky, K. M., & Hershman, D. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.3293 · Cited by 37
Chung, C. T., Lakhani, I., Chou, O. H. I., Lee, T. T. L., Dee, E. C., Ng, K., Wong, W. T., Liu, T., Lee, S., Zhang, Q., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5927 · Cited by 36
The Metabolic Syndrome and Cancer
Pistrosch, F., & Markolf Hanefeld, E. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1331-8_5 · Cited by 36
Joshi, S., Liu, M., & Turner, N. A. (2015) · BioMed Research International · doi:10.1155/2015/390863 · Cited by 36
Kumar, A., Al-Sammarraie, N., DiPette, D. J., & Singh, U. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2606 · Cited by 38
Durrani, I. A., Bhatti, A., & John, P. C. L. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02040-5 · Cited by 46
Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study
Feng, T., Sun, X., Howard, L. E., Vidal, A. C., Freedland, A. R., Moreira, D. M., Castro‐Santamaria, R., Andriole, G. L., & Freedland, S. J. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0141 · Cited by 37
Pre-diagnosis blood glucose and prognosis in women with breast cancer
Monzavi‐Karbassi, B., Gentry, R. W., Kaur, V., Siegel, E. R., Jousheghany, F., Medarametla, S., Fuhrman, B. J., Safar, A. M., Hutchins, L. F., & Kieber‐Emmons, T. (2016) · Cancer & Metabolism · doi:10.1186/s40170-016-0147-7 · Cited by 36
Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor Behind the Scene
Anwar, M. A., Kheir, W. A., Eid, S., Fares, J., Liu, X., Eid, A. H., & Eid, A. A. (2014) · Journal of Cancer · doi:10.7150/jca.9726 · Cited by 35
Targeting the autophagy pathway for cancer chemoprevention
Steeves, M. A., Dorsey, F. C., & Cleveland, J. L. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.12.013 · Cited by 37
Patel, H. Y., Younis, R. H., Ord, R. A., Basile, J. R., & Schneider, A. (2012) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2012.01196.x · Cited by 35
Simó, R., Plana‐Ripoll, O., Puente, D., Morros, R., Mundet, X., Vilca, L. M., Hernández, C., Fuentes, I., Procupet, A., Tabernero, J. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079968 · Cited by 34
Anticancer Effect of Metformin in Herceptin-Conjugated Liposome for Breast Cancer
Lee, J., Shin, D. H., & Kim, J. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics12010011 · Cited by 35
Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women
Luo, J., Chlebowski, R. T., Liu, S., McGlynn, K. A., Parekh, N., White, D. L., & Margolis, K. L. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-9996-8 · Cited by 35
Soraya, H., Esfahanian, N., Shakiba, Y., Ghazi-Khansari, M., Nikbin, B., Hafezzadeh, H., Maleki‐Dizaji, N., & Garjani, A. (2012) · Europe PMC (PubMed Central) · Cited by 35
Dickerman, B. A., García‐Albéniz, X., Logan, R. W., Denaxas, S., & Hernán, M. Á. (2023) · Epidemiology · doi:10.1097/ede.0000000000001626 · Cited by 36
Metformin: A Rising Star to Fight the Epithelial Mesenchymal Transition in Oncology
Barrière, G., Tartary, M., & Rigaud, M. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313020018 · Cited by 35
Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment,
Chevalier, S., & Farsijani, S. (2013) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2013-0369 · Cited by 36
Burton, E. R., Brady, M. F., Homesley, H. D., Rose, P. G., Nakamura, T., Kesterson, J. P., Rotmensch, J., Thigpen, J. T., & Le, L. V. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.11.027 · Cited by 34
Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents
Chen, Y., Zhao, N., Li, D., Zou, G., & Chen, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10564 · Cited by 34
Insulin Resistance: Pathophysiology and Rationale for Treatment
Muntoni, S., & Muntoni, S. (2011) · Annals of Nutrition and Metabolism · doi:10.1159/000323395 · Cited by 34
Buchs, A. E., & SILVERMAN, B. G. (2011) · Metabolism · doi:10.1016/j.metabol.2011.05.002 · Cited by 34
Cheon, Y. K., Koo, J. K., Lee, Y. S., Lee, T. Y., & Shim, C. S. (2014) · Gut and Liver · doi:10.5009/gnl.2014.8.2.205 · Cited by 34
Hall, C., Stone, R. L., Gehlot, A., Zorn, K. K., & Burnett, A. (2015) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000603 · Cited by 34
Huai, L., Wang, C., Zhang, C., Li, Q., Chen, Y., Jia, Y., Li, Y., Xing, H., Tian, Z., Rao, Q., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.001 · Cited by 33
Wu, Q., Chen, G., Wu, W., Zhou, L., You, L., Zhang, T., & Zhao, Y.-P. (2012) · Digestion · doi:10.1159/000341397 · Cited by 33
Metformin: a new option in cancer treatment
Belda-Iniesta, C., Pernía, O., & Simó, R. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0669-y · Cited by 33
Hypothesis: solid tumours behave as systemic metabolic dictators
Lee, Y., Chang, W., & Ma, W. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12794 · Cited by 35
Bergamino, M. A., Rullan, A., Saigí, M., Peiró, I., Montanya, E., Palmero, R., Ruffinelli, J. C., Navarro-Martín, A., Arnaiz, M. D., Brao, I., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5370-5 · Cited by 33
Austin, P. C., Shah, B. R., Newman, A. M., & Anderson, G. M. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03568.x · Cited by 33
Does use of metformin protect against cancer in Type 2 diabetes mellitus?
Bo, S., Benso, A. S., Durazzo, M., & Ghigo, E. (2012) · Journal of Endocrinological Investigation · doi:10.1007/bf03345423 · Cited by 33
Shi, S., He, Y., Koya, D., & Kanasaki, K. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12208 · Cited by 33
Metformin and epithelial ovarian cancer therapeutics
Patel, S. V., Kumar, L., & Singh, N. (2015) · Cellular Oncology · doi:10.1007/s13402-015-0235-7 · Cited by 32
Metformin and Gynecologic Cancers
Stine, J. E., & Bae-Jump, V. L. (2014) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000092 · Cited by 33
The Role for Insulin and Insulin-like Growth Factors in the Increased Risk of Cancer in Diabetes
LeRoith, D., Scheinman, E. J., & Bitton-Worms, K. (2011) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10043 · Cited by 33
Cantoria, M. J., Boros, L. G., & Meuillet, E. J. (2013) · Metabolomics · doi:10.1007/s11306-013-0555-4 · Cited by 33
Quattrini, I., Conti, A., Pazzaglia, L., Novello, C., Ferrari, S. M., Picci, P., & Benassi, M. S. (2013) · Oncology Reports · doi:10.3892/or.2013.2862 · Cited by 31
Is it time to test biguanide metformin in the treatment of melanoma?
Cerezo, M., Tomić, T., Ballotti, R., & Rocchi, S. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12267 · Cited by 32
Shackelford, D. B. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.116323 · Cited by 31
Holden, S. E., Jenkins‐Jones, S., & Currie, C. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153594 · Cited by 31
Jackson, A. L., Sun, W., Kilgore, J., Guo, H., Fang, Z., Yin, Y., Jones, H. M., Gilliam, T. P., Zhou, C., & Bae-Jump, V. L. (2017) · Oncotarget · doi:10.18632/oncotarget.22012 · Cited by 34
Biondo, L. A., Teixeira, A. A. S., Ferreira, K. C. D. O. S., & Neto, J. C. R. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200122124116 · Cited by 31
Inhibition of tumor energy pathways for targeted esophagus cancer therapy
Shafaee, A., Dastyar, D. Z., Islamian, J. P., & Hatamian, M. (2015) · Metabolism · doi:10.1016/j.metabol.2015.07.005 · Cited by 32
Chuang, M.-C., Yang, Y.-H., Tsai, Y.-H., Hsieh, M.-J., Lin, Y.-C., Lin, C.-K., Chen, P.-C., & Yang, T.-M. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191129 · Cited by 29
Pettit, S., Cresta, E., Winkley, K., Purssell, E., & Armes, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176941 · Cited by 31
Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes
Søndergaard, C. S., Esquivel, P. N., Dalamaga, Μ., & Magkos, F. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01344-7 · Cited by 33
Papadakos, S. P., Ferraro, D., Carbone, G., Frampton, A. E., Vennarecci, G., Kykalos, S., Schizas, D., Theocharis, S. E., & Machairas, N. (2023) · Cancers · doi:10.3390/cancers15123161 · Cited by 31
Monnier, L., Colette, C., Michel, F., Cristol, J., & Owens, D. R. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1174 · Cited by 30
Pharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 30
Antidiabetic drugs and risk of cancer
Tokajuk, A., Krzyżanowska-Grycel, E., Tokajuk, A., Grycel, S., Sadowska, A., & Car, H. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.05.005 · Cited by 30
Diabetes and cancer: A 2013 synopsis
Buysschaert, M., & Sadikot, S. S. (2013) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2013.08.001 · Cited by 29
Wang, W.-M., Xu, Y., Yang, X., Wang, Y., Sun, H., & Fan, J. (2011) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(11)60059-3 · Cited by 29
Metformin treatment for Type 2 diabetes in pregnancy?
Simmons, D. S. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.05.002 · Cited by 32
Andersen, D. K. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835eddd3 · Cited by 29
Zell, J. A., McLaren, C. E., Morgan, T. R. M., Lawson, M. J., Rezk, S. A., Albers, G. C., Chen, W., Carmichael, J. C., Chung, J., Richmond, E. S., et al. (2019) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-18-0262 · Cited by 29
Xin, H.-W., Ambe, C. M., Miller, T. C., Chen, J., Wiegand, G. W., Anderson, A. J., Ray, S., Mullinax, J. E., Hari, D. M., Koizumi, T., et al. (2016) · Journal of Cancer · doi:10.7150/jca.10047 · Cited by 28
Do metformin a real anticarcinogen? A critical reappraisal of experimental data.
Anisimov, V. N. (2014) · PubMed Central · doi:10.3978/j.issn.2305-5839.2014.06.02 · Cited by 28
Wang, Y., Lin, B., Wu, J., Zhang, H., & Wu, B. (2014) · Oncology Letters · doi:10.3892/ol.2014.2270 · Cited by 28
Metformin in lung cancer: rationale for a combination therapy
Morgillo, F., Sasso, F. C., Corte, C. M. D., Festino, L., Manzo, A., Martinelli, E., Troiani, T., Capuano, A., & Ciardiello, F. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.828691 · Cited by 29
Wu, J. W., Boudreau, D. M., Park, Y., Simonds, N. I., & Freedman, A. N. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.926887 · Cited by 27
Pivotal role of oxidative stress in tumor metastasis under diabetic conditions in mice
Ikemura, M., Nishikawa, M., Kusamori, K., Fukuoka, M., Yamashita, F., & Hashida, M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.028 · Cited by 28
The female breast and diabetes
Gouveri, E., Παπάνας, Ν., & Maltezos, E. S. (2011) · The Breast · doi:10.1016/j.breast.2011.02.019 · Cited by 28
Diabetology and oncology meet in a network model: union is strength
Gallo, M., Gentile, L., Arvat, E., Bertetto, O., & Clemente, G. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0839-z · Cited by 28
Li, S., Yang, F., Kumagai, A., Kawakita, E., Kitada, M., Kanasaki, K., & Koya, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030805 · Cited by 28
Higher risk of mortality from lung cancer in Taiwanese people with diabetes
Tseng, C. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.10.019 · Cited by 27
New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication
Gunter, J. H., Sarkar, P. L., Lubik, A. A., & Nelson, C. C. (2013) · International Journal of Cell Biology · doi:10.1155/2013/834684 · Cited by 27
Antihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 28
Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
Rebelo, R., Polónia, B. R. G., Santos, L. L., Vasconcelos, M. H., & Xavier, C. P. R. (2021) · Pharmaceuticals · doi:10.3390/ph14030280 · Cited by 30
Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis
Grossmann, M. E., Yang, D.-Q., Guo, Z., Potter, D. A., & Cleary, M. P. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-015-0032-z · Cited by 28
Metadata
- Authors
- Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A.
- Affiliations
- University of Alberta (CA)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-02-01
- Volume
- 29
- Issue
- 2
- Pages
- 254-258
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2156370651
- Cited by
- 933
- References
- 37
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 28 · 2023: 32 · 2022: 26 · 2021: 25 · 2020: 33 · 2019: 37 · 2018: 33 · 2017: 45 · 2016: 43 · 2015: 52 · 2014: 55 · 2013: 96 · 2012: 93
- FWCI
- 16.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cancer mortality, sulfonylureas, insulin therapy, metformin, antidiabetic drugs, cancer risk
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Neoplasms, Retrospective Studies, Risk Factors, Saskatchewan, Severity of Illness Index, Sulfonylurea Compounds, Cohort Studies, Comorbidity, Multivariate Analysis, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
